<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00191737</url>
  </required_header>
  <id_info>
    <org_study_id>7233</org_study_id>
    <secondary_id>B4Z-SB-LYDE</secondary_id>
    <nct_id>NCT00191737</nct_id>
  </id_info>
  <brief_title>An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder</brief_title>
  <official_title>An Open-Label Study on Effectiveness and Tolerability of Atomoxetine, as Perceived by Patients, Parents, and Physicians in Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and
      tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by
      patients, parents and physicians, and its impact on self-esteem in adolescents (aged 12
      through 17 years) with Attention-Deficit/Hyperactivity Disorder treated as outpatients in
      Germany. An 8-week treatment phase is followed by a 16-week extension period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date>February 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Impression of Perceived Difficulties (GIPD) scale at baseline, Week 8 and Week 24</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rosenberg Self-Esteem Scale (SES) during 8 and 24 weeks of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Adverse Events Rating Scale (PAERS) during 8 and 24 weeks of treatment</measure>
  </secondary_outcome>
  <enrollment>147</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients who are at least 12 years of age and who will not have
             reached their 18th birthday

          -  Diagnosis of ADHD

          -  Normal intelligence

        Exclusion Criteria:

          -  Weigh less than 30 kg or more than 85 kg at study entry

          -  Other relevant psychiatric diagnoses

          -  Are at serious suicidal risk as determined by the investigator

          -  Have a history of severe allergies

          -  Alcohol or drug abuse within the past 3 months

          -  Are female patients who are pregnant or breast-feeding. Sexually active females must
             use a medically acceptable method of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Chair</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>January 24, 2007</last_update_submitted>
  <last_update_submitted_qc>January 24, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

